The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer

Lung Cancer

Volumn 14, Issue 2-3, 1996, Pages 207-217

  Kwa, H B ^a,c   Michalides, R J A M ^b   Dijkman, J H ^a   Mooi, W J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Cyclin D1; Immunohistochemistry; NCAM; Non small cell lung carcinoma; P53 protein; Prognostic factors

Indexed keywords

CYCLINE; NERVE CELL ADHESION MOLECULE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

EID: 0029894105     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-5002(96)00547-8     Document Type: Article

References (42)

1. World Health Organization. In: The World Health Organization Histological Typing of Lung Tumours, 2nd edn. Geneva: World Health Organization, 1981.
2. Richardson GE, Johnson BE. The biology of lung cancer. Semin Oncol 1993; 20: 105-127.
3. Buccheri G, Ferrigne D. Prognostic factors in lung cancer: tables and comments. Eur Respir J 1994; 7: 1350-1364.
4. Souhami RL. Neuroendocrine phenotype, chemosensitivity and prognosis in adenocarcinoma of the lung. Ann Oncol 1991; 2: 323-324.
5. Aletsee-Ufrecht MC, Langley K, Rotsch M, Havemann K, Gratzl M. NCAM: a surface marker for human small cell lung cancer cells. FEBS Lett 1990; 267: 295-300.
6. Molenaar WM, de Leij L, Trojanowski JQ. Neuroectodermal tumors of the peripheral and the central nervous system share neuroendocrine N-CAM-related antigens with small cell lung carcinomas. Acta Neuropathol 1991; 83: 46-54.
7. Pujol JL, Simony J, Demoly P, Charpentier R, Laurent JC, Daures JP, Lehmann M, Guyot V, Godard P, Michel FB. Neural cell adhesion molecule and prognosis of surgically resected lung cancer. Am Rev Respir Dis 1993; 148: 1071-1075.
8. Kibbelaar RE, Moolenaar KE, Michalides RJ, van Bodegom PC, Vanderschueren RG. Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma. Eur J Cancer 1991; 27: 431-435.
9. Berendsen HH, de Leij L, Poppema S, Postmus PE, Boes A, Sluiter HJ, The H. Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 1989; 7: 1614-1620.
10. Moolenaar CE, Muller EJ, Schol DJ, Figdor CG, Bock E, Bitter-Suermann D, Michalides RJ. Expression of neural cell adhesion molecule-related sialoglycoprotein in small cell lung cancer and neuroblastoma cell lines H69 and CHP-212. Cancer Res 1990; 50: 1102-1106.
11. Greenwell A, Foley JF, Maronpot RR. An enhancement method for immunohistochemical staining of proliferating cell nuclear antigen in archival rodent tissues. Cancer Lett 1991; 59: 251-256.
12. McKee PH, Hobbs C, Hall PA. Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology 1993; 23: 377-379.
13. Husmann M, Pietsch T, Fleischer B, Weisgerber C, Bitter-Suermann D. Embryonal neural cell adhesion molecules on human natural killer cells. Eur J Immunol 1989; 19: 1761-1763.
14. Komminoth P, Roth J, Lackie PM, Bitter-Suermann D, Heitz PU. Polysialic acid of the neural cell adhesion molecule distinguishes small cell lung carcinoma from carcinoids. Am J Pathol 1991; 139: 297-304.
15. Acheson A, Sunshine JL, Rutishauser U. NCAM polysialic acid can regulate both cell-cell and cell-substrate interactions. J Cell Biol 1991; 114: 143-153.
16. Scheidegger EP, Lackie PM, Papay J, Roth J. In vitro and in vivo growth of clonal sublines of human small cell lung carcinoma is modulated by polysialic acid of the neural cell adhesion molecule. Lab Invest 1994; 70: 95-106.
17. Michalides R, Kwa B, Springall D, van Zandwijk N, Koopman J, Hilkens J, Mooi W. NCAM and lung cancer. Int J Cancer 1994; 8 Suppl: 34-37.
18. Johnson BE, Kelley MJ. Overview of genetic and molecular events in the pathogenesis of lung cancer. Chest 1993; 103: 1S-3S.
19. Miller CW, Simon K, Aslo A, Kok K, Yokota J, Buys CH, Terada M, Koeffler HP. P53 mutations in human lung tumors. Cancer Res 1992; 52: 1695-1698.
20. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF, Linnoila RI. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992; 7: 743-749.
21. Marchetti A, Buttitta F, Merlo G, Diella F, Pellegrini S, Pepe S, Macchiarini P, Chella A, Angeletti CA, Callahan R, Bistocchi M, Squartini F. P53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 1993; 53: 2846-2851.
22. Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, McIntire D, Slamon D, Gazdar A, Minna J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 1994; 106: 377S-381S.
23. Roncalli M, Doglioni C, Springall DR, Papotti M, Pagani A, Polak JM, Ibrahim NB, Coggi G, Viale G. Abnormal p53 expression in lung neuroendocrine tumors. Diagnostic and prognostic implications. Diagn Mol Pathol 1992; 1: 129-135.
24. Top B, Mooi WJ, Klaver SG, Boerrigter L, Wisman P, Elbers JRJ, Visser S, Rodenhuis S. P53 gene mutation and protein accumulation in human non small cell lung cancer. Int J Cancer (Pred Oncol) 1995; 64: 83-91.
25. Passlick B, Izbicki JR, Haussinger K, Thetter O, Pantel K. Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer. J Thorac Cardiovasc Surg 1995; 109: 1205-1211.
26. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992; 66: 735-738.
27. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52: 4828-4831.
28. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994; 54: 2496-2503.
29. Harpole DH Jr, Herndon JE, 2nd, Wolfer WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995; 55: 51-56.
30. Wade Harper J, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 Cyclin-dependent kinases. Cell 1993; 75: 805-816.
31. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 suppression. Cell 1993; 75: 817-825.
32. Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 1994; 9: 707-718.
33. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF, Sherr CJ. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993; 7: 1559-1571.
34. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993; 8: 2127-2133.
35. Schuuring E, Verhoeven E, van Tinteren H, Peterse JL, Nunnink B, Thunnissen FBJM, Devilee P, Cornelisse CJ, van de Vijver MJ, Mooi WJ, Michalides RJAM. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res 1993; 52: 5229-5234.
36. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm F. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995; 55: 975-978.
37. Hermanek P, Sobin LH. Lung and pleural tumours. In: UICC: TNM classification of malignant tumors, 4th edn., 2nd revision, Geneva: Springer, 1992; 75-80.
38. Beverley PCL, Souhami RL, Bobrow L. Results of the central data analysis. Lung Cancer 1988; 4: 15-36.
39. Kibbelaar RE, Moolenaar CEC, Michalides RJAM, Bitter-Suermann D, Addis B, Mooi WJ. Expression of embryonal neural cell adhesion molecule in lung carcinoma. Diagnostic usefulness of monoclonal antibody 735 for the distinction between small cell lung cancer and non-small cell lung cancer. J Pathol 1989; 159: 23-28.
40. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
41. Gerardy-Shahn R, Eckhardt M, Ledermann J, Kemshead JT. Topography of NCAM antigenic receptors recognized by SCLC-cluster-1 antibodies. A consensus view. Int J Cancer 1993; 8 Suppl: 27-79.
42. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531-539.